ADCE-D01
Soft Tissue Sarcoma
Phase 1/2Active
Key Facts
About Adcendo
Adcendo is a clinical-stage biotechnology company pioneering novel antibody-drug conjugate (ADC) therapies for cancers with significant unmet need. Its lead candidate, ADCE-D01, targeting uPARAP for soft tissue sarcoma, has entered Phase I/II trials and received FDA Fast Track designation, highlighting its potential. The company is led by a seasoned management team with direct experience in developing and commercializing multiple approved ADC drugs, positioning it strongly in the competitive oncology landscape.
View full company profileTherapeutic Areas
Other Soft Tissue Sarcoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Yondelis (trabectedin) | PharmaMar | Approved |
| Aldoxorubicin (LADR-7) | LadRx | Phase 3 |
| ADI-PEG 20 (pegargiminase) | Polaris Pharma | Phase 3 |
| Tissue Orientation System Clinical Expansion | Vector Surgical | Commercial |
| NBTXR3 | Nanobiotix | Phase II/III |